Actively Recruiting
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
Led by University of Alicante · Updated on 2026-05-07
66
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
U
University of Alicante
Lead Sponsor
H
Hospital General Universitario Dr. Balmis de Alicante
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy and bone or lymph node metastasis. The main questions it aims to answer are: * Does a low to moderate load power training program improve quality of life in people with metastatic prostate cancer under androgen deprivation therapy? * Does a low to moderate load power training program improve power, strength, endurance, and balance in people with metastatic prostate cancer under androgen deprivation therapy? Researchers will compare the exercise program with routine care to see if power training works to improve common physical side effects of androgen suppression therapy in patients with metastatic prostate cancer. Participants will: * Participate in a supervised exercise program twice a week for 6 months or maintain routine care. * Perform fitness tests and questionnaires about quality of life and mental health. * Those who take part in the exercise program will also perform semi-structured in-depth interviews after the end of the program.
CONDITIONS
Official Title
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathologically confirmed diagnosis of prostate adenocarcinoma.
- Metastatic hormone-sensitive prostate cancer (mHSPC), either present at initial diagnosis or developed after prior treatment with surgery and/or radiotherapy.
- Evidence of progression to castration-resistant prostate cancer (CRPC).
- Currently receiving a doublet treatment of standard androgen deprivation therapy combined with an androgen receptor signaling inhibitor, started before study enrollment.
- Receiving bone-protective therapy including calcium, vitamin D, and bisphosphonates.
- Metastatic disease limited to bone and/or lymph nodes.
- Functionally independent in daily activities.
You will not qualify if you...
- Presence of visceral metastatic disease.
- Current or past treatment with a triplet regimen that includes chemotherapy.
- History of pathological fracture.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alicante
San Vicent del Raspeig, Alicante, Spain, 03690
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here